APA (7th ed.) Citation

Schöffski, P., & Hohenberger, P. (2016). Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A randomised, open-label, multicentre, phase 3 trial. The lancet, 387(10028), . https://doi.org/10.1016/S0140-6736(15)01283-0

Chicago Style (17th ed.) Citation

Schöffski, Patrick, and Peter Hohenberger. "Eribulin Versus Dacarbazine in Previously Treated Patients with Advanced Liposarcoma or Leiomyosarcoma: A Randomised, Open-label, Multicentre, Phase 3 Trial." The Lancet 387, no. 10028 (2016). https://doi.org/10.1016/S0140-6736(15)01283-0.

MLA (9th ed.) Citation

Schöffski, Patrick, and Peter Hohenberger. "Eribulin Versus Dacarbazine in Previously Treated Patients with Advanced Liposarcoma or Leiomyosarcoma: A Randomised, Open-label, Multicentre, Phase 3 Trial." The Lancet, vol. 387, no. 10028, 2016, https://doi.org/10.1016/S0140-6736(15)01283-0.